See more : Balkrishna Paper Mills Limited (BALKRISHNA.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Poolbeg Pharma PLC (POLBF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Poolbeg Pharma PLC, a leading company in the Biotechnology industry within the Healthcare sector.
- Energy Focus, Inc. (EFOI) Income Statement Analysis – Financial Results
- SF Real Estate Investment Trust (2191.HK) Income Statement Analysis – Financial Results
- Salcef Group S.p.A. (SCF.MI) Income Statement Analysis – Financial Results
- CSSC Offshore & Marine Engineering (Group) Company Limited (0317.HK) Income Statement Analysis – Financial Results
- Warehouses De Pauw (WDP.BR) Income Statement Analysis – Financial Results
Poolbeg Pharma PLC (POLBF)
About Poolbeg Pharma PLC
Poolbeg Pharma plc operates as a clinical stage infectious disease pharmaceutical company in the United Kingdom. It develops POLB 001, a p38 MAP Kinase inhibitor for the treatment of severe influenza; POLB 002, an inlicensed firstinclass intranasally administered RNAbased immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis. The company also has a licensed access to micro and nanoencapsulation technology to develop an oral vaccine delivery platform that delivers immune stimulating antigens to various areas of the gut; and artificial intelligence powered drug program. In addition, it is involved in the development of biomarker platform to identify those at risk of developing severe disease; and vaccine discovery platform, a model-derived discovery platform to identify new vaccine candidates. Poolbeg Pharma plc was incorporated in 2021 and is headquartered in London, the United Kingdom.
| Metric | 2023 | 2022 | 2021 |
|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 26.00K | 26.00K | 18.00K |
| Gross Profit | -26.00K | -26.00K | -18.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% |
| Research & Development | 1.68M | 2.20M | 414.00K |
| General & Administrative | 3.38M | 3.06M | 2.03M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 |
| SG&A | 3.38M | 3.06M | 2.03M |
| Other Expenses | -26.00K | 0.00 | 0.00 |
| Operating Expenses | 5.04M | 4.99M | 2.34M |
| Cost & Expenses | 5.04M | 4.99M | 2.34M |
| Interest Income | 0.00 | 209.00K | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 26.00K | 26.00K | 18.00K |
| EBITDA | -4.66M | -4.96M | -3.09M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% |
| Operating Income | -4.69M | -4.99M | -2.34M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 181.00K | 209.00K | 0.00 |
| Income Before Tax | -4.51M | -4.78M | -2.34M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 574.00K | -91.00K | 42.00K |
| Net Income | -3.93M | -4.69M | -2.34M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% |
| EPS | -0.01 | -9.37 | -0.01 |
| EPS Diluted | -0.01 | -9.37 | -0.01 |
| Weighted Avg Shares Out | 497.59M | 500.00K | 317.23M |
| Weighted Avg Shares Out (Dil) | 500.00M | 500.00K | 317.23M |
Poolbeg Pharma PLC Announces Director Share Purchase
Poolbeg Pharma's Laura Maher discusses leading clinical innovation - ICYMI
Poolbeg Pharma chairman to take an executive role with fast-growing drugs group
Poolbeg Pharma PLC Announces Board Role Change and Launch of EIP
Poolbeg Pharma's $10bn opportunity a real value enhancer - analyst
Poolbeg Pharma points to independent research that suggests $10bn market for lead asset
Poolbeg Pharma PLC Announces Market Opportunity for POLB 001 for CRS
Poolbeg Pharma drug could help revolutionise cancer immunotherapies
Poolbeg Pharma PLC Announces Further Data Shows POLB001 Potential in Cancer CRS
Poolbeg Pharma management will look to partner RSV discoveries, says research house
Source: https://incomestatements.info
Category: Stock Reports